CoChat

Interleukin‐1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset

Open access
Cabrera, Susanne M., Wang, Xujing, Chen, Yi‐Guang, Jia, Shuang, Kaldunski, Mary L., Greenbaum, Carla J., the Type 1 Diabetes TrialNet Canakinumab Study Group, Mandrup‐Poulsen, Thomas, the AIDA Study Group, Hessner, Martin J. · 2016 · European Journal of Immunology
Cited by 56

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

It was hypothesized that IL‐1 antagonism would preserve β‐cell function in new onset Type 1 diabetes (T1D). However, the Anti‐Interleukin‐1 in Diabetes Action (AIDA) and TrialNet Canakinumab (TN‐14) trials failed to show efficacy of IL‐1 receptor antagonist (IL‐1Ra) or canakinumab, as measured by stimulated C‐peptide response. Additional measures are needed to define immune state changes associated with therapeutic responses. Here, we studied these trial participants with plasma‐induced transcriptional analysis. In blinded analyses, 70.2% of AIDA and 68.9% of TN‐14 participants were correctly called to their treatment arm. While the transcriptional signatures from the two trials were distinct, both therapies achieved varying immunomodulation consistent with IL‐1 inhibition. On average, IL‐1 antagonism resulted in modest normalization relative to healthy controls. At endpoint, signatures were quantified using a gene ontology‐based inflammatory index, and an inverse relationship was observed between measured inflammation and stimulated C‐peptide response in IL‐1Ra‐ and canakinumab‐treated patients. Cytokine neutralization studies showed that IL‐1α and IL‐1β additively contribute to the T1D inflammatory state. Finally, analyses of baseline signatures were indicative of later therapeutic response. Despite the absence of clinical efficacy by IL‐1 antagonist therapy, transcriptional analysis detected immunomodulation and may yield new insight when applied to other clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/eji.201546005

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 56

Metadata

Authors
Cabrera, S. M., Wang, X., Chen, Y., Jia, S., Kaldunski, M. L., Greenbaum, C. J., the Type 1 Diabetes TrialNet Canakinumab Study Group, Mandrup‐Poulsen, T., the AIDA Study Group, & Hessner, M. J.
Venue
European Journal of Immunology
Publisher
Wiley
Published
2016-01-21
Volume
46
Issue
4
Pages
1030-1046
ISSN
  • 0014-2980 (ISSN-L)
  • 1521-4141
OpenAlex
W2207297826
Cited by
56
References
9
FWCI
4.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.